Edgewise Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Edgewise Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($167.80M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($133.81M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($100.16M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($67.64M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($42.81M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($17.12M) | Feb 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($191.41M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($158.83M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($114.36M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($71.66M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($43.22M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($17.19M) | Feb 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $126.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $90.91M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $54.03M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $32.19M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $14.98M | Feb 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($143.82M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($109.03M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($91.95M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($52.64M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($33.51M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($14.63M) | Feb 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.31M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.75M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $5.55M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $668.0K | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $203.0K | Feb 24, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $552.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $486.82M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $340.04M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $367.10M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $285.23M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $131.14M | Feb 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.35M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $27.60M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $21.21M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $20.39M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $10.85M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.34M | Feb 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $522.26M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $459.22M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $318.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $346.72M | Feb 26, 2026 |
| FY2023 | Dec 31, 2021 | $274.38M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($33.42M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($16.85M) | Feb 24, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($546.37M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($378.58M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($244.76M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($144.60M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($76.96M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($34.15M) | Feb 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.15M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $41.67M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $86.10M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $21.99M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $15.57M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $104.92M | Feb 24, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | (23) | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | (23) | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 106.25M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 94.84M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 70.45M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 63.26M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 49.50M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 1.01M | Feb 24, 2022 |